Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate Cancer.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2023 Jun

filter terms:

The field of radionuclide therapy (RNT) for prostate cancer (PC) is growing rapidly, with recent Food and Drug Administration approval of the first 177Lu-PSMA ligand. We aimed to develop the first patient-reported outcome (PRO) measure for PC patients receiving RNT. Methods: We identified relevant symptoms and toxicities by reviewing published trials and interviews with PC patients receiving RNT (n = 29), caregivers (n = 14), and clinicians (n = 11). Second, we selected items for measure inclusion. Third, we refined the item list with input from experts in RNTs and PROs. Fourth, we finalized the Functional Assessment of Cancer Therapy-Radionuclide Therapy (FACT-RNT) with patient input. Results: This multistep process yielded a brief 15-item measure deemed by key stakeholders to be relevant and useful in the context of RNT for PC. Conclusion: The FACT-RNT is a new standardized tool to monitor relevant symptoms and toxicities among PC patients in RNT trials and real-world settings. © 2023 by the Society of Nuclear Medicine and Molecular Imaging.

Citation

Lisa M Gudenkauf, Melody N Chavez, Melinda Leigh Maconi, Carley Geiss, Ameen Seyedroudbari, Pan Thin, Aasha I Hoogland, Kathleen Nguyen, Vishnu Murthy, Wesley R Armstrong, Khaled Komrokji, Laura B Oswald, Heather S L Jim, Ghassan El-Haddad, Wolfgang P Fendler, Ken Herrmann, David Cella, Johannes Czernin, Michael S Hofman, Adam P Dicker, Jeremie Calais, Scott T Tagawa, Brian D Gonzalez. Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate Cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2023 Jun;64(6):869-872